Hospira names Richard Davies as chief commercial officer

Brings 20 years’ experience to the role

Hospira, a US provider of injectable drugs and infusion technologies based in Lake Forest, Illinois, has appointed Richard Davies as senior vice president and chief commercial officer.

In this role, which he starts tomorrow (2 February), Davies will be responsible for developing and executing Hospira’s global commercial strategies and delivering revenue growth across the company’s product portfolio.

Davies brings more than 20 years of diverse strategic and operational experience to Hospira gained through a variety of commercial management positions and across a range of products and technologies.

Most recently, he was vice president and general manager, Japan, Asia Pacific and Latin America, for Amgen, where he was responsible for establishing Amgen's business in the region as well as supporting its strategy development for emerging markets overall. During his eight years at Amgen, he led the company’s commercial organisations in Central/Eastern Europe and Australia, and also served as vice president of US sales for the immunology franchise.

Prior to joining Amgen, Davies spent 13 years at Eli Lilly in roles of increasing commercial responsibility, including general country management.

You may also like

Drug Delivery

Mylan and Hospira voluntarily recall injectables

Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been reported as yet
Regulatory

Brussels explains why it approved Pfizer/Hospira deal

Pfizer made a commitment to remove possible product overlaps between the two companies
Regulatory

Hospira calls for biosimilars to have same name as biologicals

Different names for a biologic and the biosimilar medicine patterned on that biologic could create confusion among clinicians
Research & Development

Hospira and Pfenex link up to develop Lucentis biosimilar

Pfenex will receive US$51m upfront once the collaboration receives antitrust approval
Drug Delivery

Pfizer to acquire Hospira

Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira
Regulatory

Biosimilars need the same names as original biologics

Proper naming of biosimilars is key for patient access and safety, say delegates at WHO INN meeting
Media

Asia and Latin America will drive biosimilars growth in next decade, says Visiongain

Established players will focus on monoclonal antibodies and licensing deals
Subscribe now